CELLECTIS - ADR (CLLS) Stock Analyst Ratings
USA - NASDAQ:CLLS - US15117K1034 - ADR
3.48 USD
+0.01 (+0.29%)
ChartMill assigns a Buy % Consensus number of 85% to CLLS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.46. This target is 114.45% above the current price.
CLLS was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CLLS.
In the previous month the buy percentage consensus was at a similar level.
CLLS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-13 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-06-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-31 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-01 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-08 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-08-07 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-04-05 | Citigroup | Maintains | Buy |
| 2023-03-13 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-13 | Oppenheimer | Maintains | Outperform |
| 2023-01-19 | JMP Securities | Maintains | Market Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-18 | Baird | Upgrade | Neutral -> Outperform |
| 2022-05-13 | Barclays | Maintains | Overweight |
| 2022-01-06 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2021-11-30 | JMP Securities | Initiate | Market Outperform |
| 2021-10-08 | Baird | Downgrade | Outperform -> Neutral |
CELLECTIS - ADR / CLLS FAQ
What is the average price target for CELLECTIS - ADR (CLLS) stock?
13 analysts have analysed CLLS and the average price target is 7.46 USD. This implies a price increase of 114.45% is expected in the next year compared to the current price of 3.48.
Can you provide the consensus rating for CELLECTIS - ADR stock?
The consensus rating for CELLECTIS - ADR (CLLS) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.